22 completed, 5 terminated, 2 unknown. 17 Phase 2, 13 Phase 1, 2 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 13, Terminated 3, Unknown 1 |
| Phase 1 | 13 | Completed 10, Unknown 2, Terminated 1 |
| Early Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Terminated 1 |
Follow MART-1 Antigen: new trials by email Literature Review of MART-1 Antigen trials Research Report on MART-1 Antigen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery MART-1 Antigen, TLR4 Agonist GLA-SE, Laboratory Biomarker Analysis - Stage IIA Skin Melanoma, Stage IIB Skin Melanoma | Early Phase 1 | Completed | Mayo Clinic | 23 | 2015-01-27 | 2020-01-14 |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Montanide ISA 51 VG, MART-1 antigen, laboratory biomarker analysis - Recurrent Melanoma, Stage IIA Melanoma | Early Phase 1 | Completed | Mayo Clinic | 30 | 2012-10-01 | 2018-10-09 |
| Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12 - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 10 | 2011-02-01 | 2016-10-24 |
| Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 MART-1, NY-ESO-1, gp100:209-217(210M) - Melanoma (Skin) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 127 | 2010-08-04 | 2023-01-18 |
| Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma MART-1 antigen, IL-2, gp100 antigen - Melanoma (Skin) | Phase 1 | Completed | Mayo Clinic | 20 | 2007-03-01 | 2019-02-19 |
| LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery LMB-2 immunotoxin, MART-1 antigen, gp100 antigen - Melanoma (Skin), Non-melanomatous Skin Cancer | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 26 | 2005-12-01 | 2012-06-14 |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma cyclophosphamide, fludarabine phosphate, therapeutic autologous lymphocytes - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 58 | 2005-11-01 | 2013-06-06 |
| Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients Melan-A, Melan-A plus Dacarbazine - Melanoma | Phase 1 | Completed | Istituto Superiore di Sanità | 10 | 2004-09-01 | 2007-11-16 |
| Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Melanoma (Skin) | Phase 1 | Completed | National Cancer Institute (NCI) | 2004-08-01 | 2015-04-30 | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma tyrosinase peptide, gp100 antigen, MART-1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-06-01 | 2015-04-15 |
| Immunotherapy of Stage III/IV Melanoma Patients Melan-A ELA + Montanide, Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide, Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG - Melanoma | Phase 1 | Completed | Centre Hospitalier Universitaire Vaudois | 39 | 2004-02-01 | 2020-06-18 |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 6 | 2003-10-01 | 2014-05-21 |
| Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin - Melanoma (Skin) | Phase 1 / Phase 2 | Completed | University Hospital Erlangen | 82 | 2003-07-01 | 2015-05-12 |
| Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 60 | 2002-02-01 | 2014-05-22 |
| Vaccine Therapy in Treating Patients With Melanoma of the Eye MART-1 antigen, NA17-A antigen, gp100 antigen - Intraocular Melanoma | Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 13 | 2002-02-01 | 2012-09-24 |
| Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Intraocular Melanoma, Melanoma (Skin) | Phase 1 | Completed | University of Southern California | 19 | 2001-10-01 | 2014-05-22 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma MAGE-10.A2, MART-1 antigen, NY-ESO-1 peptide vaccine - Melanoma (Skin) | Phase 1 | Unknown | Herbert Irving Comprehensive Cancer Center | 2001-10-01 | 2013-12-18 | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye gp100 antigen, interleukin-2, MART-1 antigen - Extraocular Extension Melanoma, Recurrent Intraocular Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 2001-02-01 | 2024-03-04 | |
| Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma MART-1 antigen, gp100 antigen - Melanoma (Skin) | Phase 1 / Phase 2 | Unknown | Genzyme, a Sanofi Company | 2000-11-01 | 2014-01-06 | |
| Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Melanoma (Skin) | Phase 2 | Completed | Eastern Cooperative Oncology Group | 2000-09-01 | 2011-11-08 |
Showing 20 of 29. Sign in to see all of them.
Melanoma (27) · Uveal Melanoma (7) · Neoplasms (3) · Skin Neoplasms (2) · Carcinoma, Renal Cell (1) · Eye Neoplasms (1) · Neoplasm Metastasis (1) · Urologic Neoplasms (1)
National Cancer Institute (NCI) (10) · University of Southern California (5) · Mayo Clinic (3) · Baylor Health Care System (1) · Centre Hospitalier Universitaire Vaudois (1) · Eastern Cooperative Oncology Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Genzyme, a Sanofi Company (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Herbert Irving Comprehensive Cancer Center (1) · Istituto Superiore di Sanità (1) · National Institutes of Health Clinical Center (CC) (1) · University Hospital Erlangen (1) · University of Chicago (1)
United States (25) · Belgium (1) · Denmark (1) · Germany (1) · Italy (1) · Switzerland (1)
Jeffrey S. Weber, MD, PhD (5) · Steven A. Rosenberg, MD, PhD (4) · Amy E. Bock (1) · Enrico Proietti, M.D. (1) · Francesco M. Marincola (1) · Gerold Schuler (1) · James C. Yang, MD (1) · Jan U. Prause, MD (1) · Jeffrey Weber (1) · John M. Kirkwood, MD (1) · Joseph W. Fay, MD (1) · Kyriakos P. Papadopoulos, MD (1) · Mario Roselli, M.D. (1) · Matthew Block (1) · Nikhil I. Khushalani, M.D. (1)
PMID 12684398, PMID 16699374, PMID 19228745, PMID 22021080, PMID 24145345, PMID 25277238, PMID 25808864, PMID 27853637, PMID 31015344, PMID 32752904, PMID 33955240
P30CA015083 (2), N01CM00071 (1), P30CA014599 (1)